Literature DB >> 2839394

Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.

T S Maughan1, R G Fish, M Shelley, B Jasani, G T Williams, M Adams.   

Abstract

The presence of cancer antigen CA125 has been assessed immunohistologically in formalin-fixed tumor tissue and immunoradiometrically in serum from 41 women with residual epithelial ovarian carcinoma after diagnostic laparotomy. CA125 was detected in tumor tissue from the majority of patients (34/41), including those with normal serum levels (15/18). The major determinant of serum CA125 concentration appears to be the size of the residual tumor. The results suggest that in the majority of patients with small residual tumor masses and normal postoperative serum antigen levels, progressive disease may well be associated with increasing serum CA125 levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839394     DOI: 10.1016/0090-8258(88)90248-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  CA125 in ovarian tumour tissue at second laparotomy.

Authors:  T S Maughan; R G Fish; M D Shelley; B Jasani; G T Williams; M Adams
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

2.  Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

Authors:  O Mogensen; B Mogensen; A Jakobsen
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

3.  CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels.

Authors:  Yi-Sheng Wang; Shi-Fang Ren; Wei Jiang; Jia-Qi Lu; Xiao-Yan Zhang; Xiao-Ping Li; Rui Cao; Cong-Jian Xu
Journal:  Ann Transl Med       Date:  2021-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.